Advertisement
Document › Details
Cellink AB. (8/27/20). "Press Release: Cytena and AstraZeneca Collaborate to Develop Plate Based Microbioreactors for Cell Line Development Workflows".
Organisation | Cytena Bioprocess Solutions Co., Ltd. (TW) | |
Group | Bico (Group) | |
Organisation 2 | AstraZeneca (Group) | |
Product | bioreactor | |
Product 2 | cell line development (research assays) | |
Index term | Cytena–Cellink: investment, 201908 acquisition €30.25m of Cytena GmbH by Cellink AB | |
Person | Gatenholm, Erik (Cellink 201908 CEO + Co-Founder RESIGNED as CEO of Bico 11/23 LEFT Board 5/24) | |
Cytena GmbH and its affiliate cytena Bioprocess Solutions Ltd., part of CELLINK Life Sciences, announced today that they will collaborate with AstraZeneca to develop a new generation of plate-based microbioreactors that can improve the efficiency of cell line development workflows. Cytena, which focuses on developing and commercializing innovative single-cell isolation and cultivation technologies, says that its collaboration with AstraZeneca will also explore machine learning algorithms for enhanced single-cell cloning.
This collaboration will leverage Cytena’s recent technological advances in the field of single-cell isolation and bioprocessing to increase efficiency and shorten timelines in the discovery and production of therapeutic antibodies. Therapeutic antibodies are biopharmaceuticals widely used in the treatment of cancer, autoimmune and inflammatory diseases; they are also used for targeted drug delivery.
Cytena is a CELLINK company based in Freiburg, Germany, and Taipei, Taiwan.
For further information, please contact:
Erik Gatenholm, CEO
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
Email: eg@cellink.com
Gusten Danielsson, CFO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138
Email: gd@cellink.com
About CELLINK
CELLINK is a global life-science company providing technologies, products, and services to create, understand, and master cell and molecular biology, with a focus on three main application areas: bioprinting, analysis, and liquid handling & bioprocessing. The company develops and markets innovative cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016, CELLINK’s products have been adopted by researchers and scientists in more than 1,000 laboratories with more than 100 publication citations, the majority of the largest pharmaceutical companies and has been delivered to more than 55 countries around the world. The company’s vision is to create the future of medicine.
Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.
Record changed: 2023-06-05 |
Advertisement
More documents for Bico (Group)
- [1] Bico Group AB. (3/15/24). "Press Release: Founders Leave after Eight Years"....
- [2] Bico Group AB. (11/13/23). "Press Release: BICO Has Divested Ginolis through a Management Buy-out to Ginolis’ Current CEO Kauko Väinämö. The Purchase Price amounted to €1"....
- [3] Bico Group AB. (11/13/23). "Press Release: Maria Forss Assumes Office as BICO’s CEO and President on November 20, 2023"....
- [4] Bico Group AB. (10/11/23). "Press Release: Cellink and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence". San Diego, CA....
- [5] Bico Group AB. (8/21/23). "Press Release: Maria Forss Is Appointed New President and CEO of Bico Group AB (publ)"....
- [6] Bico Group AB. (8/21/23). "Press Release: Bico Announces Goodwill Impairment Predominantly Due to Increased WACC, and Write-downs of Assets"....
- [7] Bico Group AB. (8/3/23). "Press Release: Bico Divests Berlin Property for a Total of EUR 21m"....
- [8] Bico Group AB. (2/27/23). "Press Release: Bico Introduces New Life Sciences Manufacturing Platform Integrating ABB Robotics Technology"....
- [9] Bico Group AB. (1/2/23). "Press Release: Bico Group Appoints New CFO"....
- [10] Sartorius AG. (12/8/22). "Press Release: Sartorius Agrees with Bico on Strategic Cooperation as well as a 10 Percent Capital Investment". Göttingen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top